GLP-1 medications — led by semaglutide (Ozempic®, Wegovy®) and tirzepatide (Mounjaro®, Zepbound®) — have fundamentally transformed the medical weight loss landscape. In 2026, more than 12% of American adults are taking these medications, the US obesity rate has declined from its 2022 peak, and the global market has surpassed $132 billion. This page compiles the most up-to-date statistics, clinical data, and market research available.

Section 01

US Obesity Statistics 2026

Understanding where America stands on obesity is essential context for GLP-1 prescribing trends. The data in 2026 shows the first meaningful, sustained decline in the US adult obesity rate in decades — a trend directly correlated with increased GLP-1 adoption.

36.4%
US adult obesity rate in 2026 — down from a 2022 peak of 39.9%
~100M
American adults currently living with obesity
50%
Projected share of US adults who will meet obesity criteria by 2030 without intervention
US Adult Obesity Rate 2018–2026 (%)
Source: Gallup Health Survey, CDC. Shows the first sustained decline from the 2022 peak, correlating with GLP-1 adoption.
📉

Historic Decline in Progress

After peaking at a record high of 39.9% in 2022, the US adult obesity rate has gradually dropped to 36.4% in 2026 — a statistically meaningful decline that continues to inversely track with increased GLP-1 usage nationally, according to Gallup’s June 2026 survey of 5,065 adults.

This decline represents the first time in modern tracking history that US obesity rates have shown a consistent multi-year downward trend. Researchers have directly attributed this to the widespread adoption of GLP-1 receptor agonists. A full 91% of Americans are now aware of GLP-1 drugs for weight loss — up from 80% in 2024.

Obesity Rates by US State Context

While national obesity rates are declining, significant geographic variation remains. States where GoalBMI Wellness serves patients show particularly high demand for evidence-based medical weight loss programs:

StateAdult Obesity RateAdults with Obesity (Est.)GLP-1 Access via GoalBMI
New York28.1%~3.8MAvailable ✓
New Jersey28.4%~2.1MAvailable ✓
Pennsylvania34.4%~3.6MAvailable ✓
Connecticut28.0%~830KExpanding ✓
National Average36.4%~100M—

📍 Physician-Supervised Programs in These States

Medical Weight Loss New York Medical Weight Loss New Jersey Medical Weight Loss Pennsylvania
Section 02

GLP-1 Usage Statistics in the US 2026

The number of Americans taking GLP-1 medications has grown at a remarkable pace. What was a relatively niche prescription category just three years ago is now one of the most widely recognized and used drug classes in the country.

% of US Adults Taking GLP-1 Medications (2024–2026)
Source: Gallup Health Survey. Usage more than doubled between February 2024 and June 2026.
Key Finding: The percentage of US adults taking GLP-1 drugs for weight loss more than doubled between February 2024 (5.8%) and June 2026 (12.4%), according to Gallup research. That represents over 10 million Americans currently using these medications.

Who is Using GLP-1 Medications?

👥

~10 Million Americans Used GLP-1 Medications in 2025

As of 2025, approximately 10 million individuals in the US used GLP-1 medications — a number expected to significantly increase through 2026 and 2027 as pricing becomes more accessible and awareness continues to grow. Source: Forbes Health, 2026

🏢

Employer Coverage of GLP-1s Surges

As of 2025, 43% of firms with over 5,000 workers now cover GLP-1 medications for obesity — up from just 28% the prior year. This dramatic expansion of employer coverage is one of the key drivers of increased adoption among working-age Americans.

💊

Medicaid Prescriptions: 1.3M to 8.4M

KFF found that the number of Medicaid prescriptions for GLP-1s increased from 1.3 million in 2019 to 8.4 million in 2024 — a 546% increase. Medicaid gross spending on GLP-1s grew from $1 billion to $8.6 billion over the same period. Source: Pew Research, January 2026

Persistence & Discontinuation Rates

A major clinical concern with GLP-1 medications is long-term adherence. Research from IQVIA tracking over 8.6 million patients shows:

MetricGLP-1 for DiabetesGLP-1 for Obesity
Continued filling prescriptions after 1 year (retail)~72%~66.5%
Discontinued within 1 year~28%~33.5%
Primary reason for stoppingSide effects / costCost / insurance

These persistence rates highlight the importance of physician-supervised programs with ongoing monitoring and support — which is a core feature of GoalBMI Wellness telehealth programs.

Section 03

GLP-1 Market Size & Sales Data 2025–2026

The financial scale of the GLP-1 market is staggering. In 2025 alone, GLP-1 therapies generated approximately $132 billion in global sales — a 33.5% increase from 2024. The anti-obesity market is now the fourth largest pharmaceutical market globally, with a pipeline of 190 obesity-related products in development.

GLP-1 Drug Sales by Brand — 2025 (USD Billions)
Source: IQVIA / AMCP Annual Meeting 2026. Tirzepatide products dominate both diabetes and obesity categories.
$39.1B
Mounjaro (tirzepatide) 2025 global sales — up 67.1% from 2024
$22.9B
Zepbound (tirzepatide) 2025 sales — up 188.7% in just 2 years
$18.6B
Wegovy (semaglutide) 2025 sales — up 29.2% from prior year
Market Context: Tirzepatide-based products (Mounjaro + Zepbound) generated over $62 billion in combined 2025 sales — making Eli Lilly’s dual GLP-1/GIP agonist the dominant force in both the diabetes and obesity markets. The anti-obesity segment is growing faster than any other major pharmaceutical category.

GLP-1 Revenue Growth Trend

Global GLP-1 Market Revenue Growth 2021–2025 (USD Billions)
Source: IQVIA, Novo Nordisk, Eli Lilly filings. Market has grown 10x in 4 years.
🏭

190 Obesity Drugs in the Pipeline

According to IQVIA’s 2026 analysis, the obesity drug pipeline now contains 190 products in development — including next-generation GLP-1 combinations, oral formulations, and triple-receptor agonists. The anti-obesity market is expected to continue growing at unprecedented rates into 2027 and beyond. Source: AMCP Annual 2026

Section 04

Clinical Trial Data: Weight Loss Outcomes

The clinical evidence for GLP-1 and GLP-1/GIP medications is among the strongest ever seen for a pharmacological obesity intervention. Here is what the major trials have shown:

Average Weight Loss by Medication — Major Clinical Trials
Sources: STEP-1 (semaglutide), SURMOUNT-1 (tirzepatide), SURMOUNT-4 (long-term tirzepatide), SURPASS-2 (head-to-head). % of body weight lost.

Weight Loss by Medication and Dose

MedicationBrand NamesTrialAvg. Weight LossDurationSource
Tirzepatide (highest dose) Zepbound® / Mounjaro® SURMOUNT-1 ~22.5% 72 weeks NEJM 2022
Tirzepatide (average) Zepbound® / Mounjaro® SURMOUNT-1 ~20-21% 72 weeks NEJM 2022
Tirzepatide (T2DM patients) Mounjaro® SURPASS-2 ~15% 40 weeks NEJM 2021
Semaglutide 2.4mg Wegovy® STEP-1 ~15% 68 weeks NEJM 2021
Semaglutide (T2DM) Ozempic® STEP-2 ~10% 68 weeks NEJM 2021
Key Insight: Patients without type 2 diabetes who take tirzepatide achieve significantly greater weight loss than those with diabetes — an average 21% vs 15% reduction. The exact mechanism for this difference is still being studied. This makes tirzepatide particularly powerful for patients pursuing weight management as a primary goal.

Weight Loss Progress Over Time — Semaglutide

Understanding how weight loss unfolds over time helps set realistic expectations:

Semaglutide Weight Loss Progression Over 68 Weeks (STEP-1)
Weight loss begins within the first 4 weeks and is greatest at 3–6 months, continuing to steady progress through week 68.

📖 Related Articles from GoalBMI Wellness

Semaglutide vs Tirzepatide: Complete Comparison Guide Tirzepatide Side Effects: Complete Patient Guide Rebound Weight Gain After Stopping Tirzepatide
Section 05

GLP-1 Pricing & Access in 2026

One of the biggest barriers to GLP-1 access has historically been cost. The pricing landscape in 2026 has changed significantly, with new government negotiations and competition making these medications more accessible than ever before.

MedicationBrandPrevious Monthly CostTrumpRx Price (2026)Oral Version
Semaglutide Ozempic® / Wegovy® ~$900–$1,300/mo $245/mo ✓ Approved Dec 2025 from $149/mo
Tirzepatide Mounjaro® / Zepbound® ~$1,000–$1,400/mo $245/mo In development
💊

First Oral GLP-1 for Obesity Approved December 2025

In December 2025, the FDA approved an oral formulation of Wegovy (semaglutide) for chronic weight management — the first oral GLP-1 to treat obesity. The starting 1.5 mg dose is available at $149/month for cash-pay patients, significantly lowering the barrier to entry for patients who prefer not to inject. Source: VytlOne, 2026

Insurance Coverage Expansion

Medicaid GLP-1 Prescriptions vs Spending Growth (2019–2024)
Source: KFF, January 2026. Medicaid prescriptions grew 546% while spending grew 760% over this period.

As of January 2026, a growing number of state Medicaid plans now cover one or more GLP-1 receptor agonists for obesity treatment under fee-for-service programs. Employer coverage has also expanded dramatically — from 28% to 43% of large employers in just one year.

Section 06

Key Milestones: The GLP-1 Revolution Timeline

The rise of modern GLP-1 medications for obesity is one of the fastest adoption stories in pharmaceutical history. Here are the key milestones:

2021
FDA Approves Wegovy (Semaglutide) for Weight Loss
Novo Nordisk’s Wegovy becomes the first major GLP-1 approval specifically for chronic weight management. STEP-1 trial shows 15% average body weight loss. This marks the beginning of the modern obesity drug era. FDA announcement
2022
US Obesity Rate Peaks at 39.9% — SURMOUNT-1 Published
The US adult obesity rate reaches its all-time recorded high. Simultaneously, the landmark SURMOUNT-1 trial is published in the New England Journal of Medicine, showing tirzepatide achieves up to 22.5% body weight loss — significantly outperforming semaglutide.
Nov 2023
FDA Approves Zepbound (Tirzepatide) for Obesity
Eli Lilly’s Zepbound receives FDA approval for chronic weight management — the most effective approved obesity drug to date. The dual GLP-1/GIP mechanism immediately positions it as the market leader for weight loss outcomes. FDA prescribing information
2024
10M+ Americans on GLP-1s — Employer Coverage Expands
Approximately 10 million Americans use GLP-1 medications. Employer coverage jumps from 28% to 43% of large firms. Medicaid GLP-1 prescriptions reach 8.4 million. Awareness among US adults climbs to 80%.
Nov 2025
TrumpRx Announcement — $245/Month Price Cap
The Trump administration announces negotiated price agreements with Novo Nordisk and Eli Lilly, capping Ozempic, Wegovy, Mounjaro, and Zepbound at $245/month through TrumpRx — less than half of prior costs.
Dec 2025
First Oral GLP-1 for Obesity Approved
FDA approves an oral version of semaglutide (Wegovy) for weight management — starting at $149/month. This eliminates the injection barrier for a significant segment of patients and opens GLP-1 treatment to a broader population.
2026
12.4% of US Adults on GLP-1s — Obesity Rate Falls to 36.4%
Gallup’s June 2026 survey finds 12.4% of US adults are currently taking GLP-1 drugs — more than double the 5.8% rate from February 2024. US obesity rate falls to 36.4%, the lowest since 2018. Global GLP-1 sales exceed $132 billion. 91% of Americans now aware of GLP-1 medications.
Section 07

What’s Next: GLP-1 Outlook for 2027 and Beyond

The GLP-1 landscape is evolving rapidly. Here are the most important developments to watch in the coming year:

🔬

190 Obesity Drugs in the Pipeline

IQVIA’s 2026 analysis identified 190 obesity-related products currently in pharmaceutical development. This includes next-generation GLP-1 combinations, triple agonists, oral formulations, and combination therapies. The competition in this space is expected to drive prices down further and outcomes up significantly.

💊

Retatrutide: 71.2 lbs Average Weight Loss in Trials

Eli Lilly’s experimental triple agonist retatrutide delivered weight loss of up to an average of 71.2 lbs in Phase 2 trials — representing the most dramatic pharmacological weight loss results ever recorded. If approved, it would represent another step-change in outcomes comparable to what tirzepatide was to semaglutide. Source: NEJM, 2023

🏥

Telehealth GLP-1 Access Expanding Rapidly

The intersection of telehealth platforms and GLP-1 prescribing is one of the fastest-growing segments of digital health. Physician-supervised telehealth programs — like those offered by GoalBMI Wellness — provide patients with the clinical oversight needed to use these powerful medications safely and effectively, without in-person office visits.

Projection: With 190 drugs in the pipeline, continued expansion of insurance coverage, TrumpRx pricing making medications more affordable, and the addition of oral GLP-1 options, the number of Americans on these medications is projected to grow significantly through 2027. Some forecasts suggest the US GLP-1 user population could reach 30-40 million by 2030.
Section 08

Frequently Asked Questions

According to Gallup’s June 2026 survey of 5,065 US adults, 12.4% of American adults are currently taking GLP-1 medications — representing approximately 32 million adults. This more than doubled from 5.8% in February 2024. An earlier estimate from Forbes Health put the 2025 user base at approximately 10 million.
Based on published clinical trial data, tirzepatide (Zepbound®/Mounjaro®) produces the greatest average weight loss — approximately 20-22.5% of body weight in the SURMOUNT-1 trial at 72 weeks. Semaglutide (Wegovy®) produces approximately 15% average weight loss in the STEP-1 trial at 68 weeks. Individual results vary based on dose, adherence, diet, and health status. Eligibility must be determined by a licensed provider.
Following the TrumpRx pricing agreements announced in November 2025, Ozempic, Wegovy, Mounjaro, and Zepbound are available at $245 per month through the TrumpRx program — less than half of prior market prices. The new oral semaglutide (Wegovy pill) starts at $149/month for cash-pay patients. Compounded versions may be available through licensed 503A pharmacies at lower costs in some cases. GoalBMI Wellness offers program pricing and insurance verification — see wellness.goalbmi.com/pricing/.
The data strongly suggests a correlation. After peaking at a record high of 39.9% in 2022, the US adult obesity rate has dropped to 36.4% in 2026 — a statistically meaningful decline. Gallup notes this decline “continues to inversely track with increased usage of GLP-1 medicine nationally.” While causation is difficult to prove definitively at a population level, the timing and direction of the relationship are consistent with GLP-1 adoption driving the obesity rate decline.
GoalBMI Wellness offers physician-supervised GLP-1 programs entirely via telehealth — no office visits required. Eligible patients in New York, New Jersey, Pennsylvania, and other participating states can complete an online intake form, have a video consultation with a licensed provider, and if appropriate receive a prescription and ongoing follow-up care. Visit wellness.goalbmi.com/contacts/ to get started or call +1-347-407-7611.
References

Sources & Medical References

This statistics page was compiled from the following peer-reviewed studies, clinical trials, government data, and authoritative research organizations:

  • 1Gallup Health Survey (June 2026). “In U.S., GLP-1 Usage Reaches New High.” Survey of 5,065 adults. gallup.com
  • 2IQVIA / AMCP Annual Meeting (2026). “GLP-1 drugs to drive growth in obesity and diabetes treatment.” managedhealthcareexecutive.com
  • 3Jastreboff A.M. et al. (2022). “Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1).” New England Journal of Medicine, 387(3), 205–216. doi.org/10.1056/NEJMoa2206038
  • 4Frías J.P. et al. (2021). “Tirzepatide versus Semaglutide in Type 2 Diabetes (SURPASS-2).” NEJM, 385(6), 503–515. doi.org/10.1056/NEJMoa2107519
  • 5Forbes Health (June 2026). “GLP-1 Statistics & Trends: Usage, Market Size, Pricing & Research 2026.” forbes.com
  • 6Pew Research Center (January 2026). “6 facts about obesity and GLP-1 weight loss drugs in the US.” pewresearch.org
  • 7KFF (January 2026). State Medicaid coverage of GLP-1s for obesity — fee-for-service analysis.
  • 8HLTH.com (April 2026). “GLP-1 Drugs, Digital Health & Obesity Trends in 2026.” hlth.com
  • 9U.S. Food & Drug Administration (2023). Zepbound (tirzepatide) prescribing information. accessdata.fda.gov
  • 10National Institute of Diabetes & Digestive & Kidney Diseases (2023). Prescription medications to treat overweight & obesity. niddk.nih.gov
  • 11VytlOne (March 2026). “The GLP-1 Market in 2026.” vytlone.com
KM

Medically Reviewed by Karla K. Mioduchoski, FNP-BC

Board-Certified Family Nurse Practitioner — GoalBMI Wellness

Karla K. Mioduchoski, FNP-BC, is a board-certified Family Nurse Practitioner providing physician-supervised medical weight loss, GLP-1 support, peptide therapy, and wellness-focused telehealth care through GoalBMI Wellness. Statistics and clinical data in this article were reviewed for accuracy and clinical relevance in July 2026.

Before and after tirzepatide and semaglutide weight loss results — GoalBMI Wellness New Brunswick Tirzepatide pricing and self-pay weight loss program — GoalBMI Wellness New Brunswick
Medical Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice and should not replace consultation with a qualified healthcare provider. Statistical data is sourced from independent research organizations, clinical trials, and government agencies as cited. Treatment decisions, including the use of GLP-1 medications, should always be made in partnership with a licensed medical professional. GoalBMI Wellness provides physician-supervised telehealth programs for eligible patients in participating states. In a medical emergency, call 911.